At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 29 enrolled
Drug / intervention
rDEN3-3'D4delta30 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3-3'Ddelta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jul 10, 2008·Updated Jan 3, 2013
In Brief
A Phase 1 clinical trial evaluating rDEN3-3'D4delta30 for Dengue. Completed, enrolled 29 participants across 2 sites.
Detailed Summary
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to evaluate the safety of and immune response to a new dengue virus vaccine in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartDec 2008
Primary CompletionSep 2009
TodayJul 2026
First PostedJul 10, 2008
Enrollment StartDec 1, 2008
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.0 years ago
Interventions
rDEN3-3'D4delta30biological
Live attenuated 10\^3 dose of rDEN3-3'D4delta30 vaccine.
rDEN3-3'D4delta30biological
Live attenuated 10\^5 dose of rDEN3-3'D4delta30 vaccine.
rDEN3-3'D4delta30biological
Live attenuated 10\^1 dose of rDEN3-3'D4delta30 vaccine.